Healthcare Industry News: AngioDynamics
News Release - September 27, 2012
AngioDynamics Bolsters Senior Leadership Team With Key AppointmentsALBANY, N.Y., Sept. 27, 2012 -- (Healthcare Sales & Marketing Network) -- AngioDynamics (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of Louis J. Mazzarese, Senior Vice President and Chief Regulatory Officer, effective October 3, 2012, and John Soto, Senior Vice President, Global Franchise, Peripheral Vascular, effective immediately. Mr. Mazzarese and Mr. Soto will report to President and CEO Joseph M. DeVivo.
"Lou and John are excellent additions to AngioDynamics' executive team, bringing with them significant leadership experience in the global medical device industry," Mr. DeVivo said. "Lou's expertise in accelerating product timelines while maintaining the highest levels of regulatory compliance will help expand the Company's product portfolio, while John will leverage his cross-functional experience and familiarity with AngioDynamics to drive growth in our PV franchise."
Mr. Mazzarese brings more than 40 years of medical device and pharmaceutical experience, including driving strategic planning and professional development within the industry through his consulting practice. Mr. Mazzarese's previous experience includes serving as Chief Regulatory Officer and Vice President, Corporate Regulatory Affairs for Edwards Lifesciences; Vice President of Regulatory and Clinical Affairs at Tyco Healthcare; and Vice President of Quality and Regulatory/Clinical Affairs at U.S. Surgical. Earlier in his career, he gained management experience at Pfizer-Shiley, Squibb Corporation, Ciba-Giegy, American McGaw and International Pharmaceutical Products. Additionally, Mr. Mazzarese, who has a B.S. and M.S. in chemistry from Wagner College in Staten Island, N.Y., is past President and Chairman of the Regulatory Affairs Professional Society and a co-founder of the Association of Disposable Device Manufacturers.
Mr. Soto has an expansive background spanning from sales and marketing to international markets and regulatory environments, as well as finance and operations. Most recently he was Senior Vice President of Smith & Nephew's Global Hip Franchise. Mr. Soto is the former Senior Vice President of Global Sales for AngioDynamics -- a role that he took on after the Company's acquisition of RITA Medical Systems in 2007, where he had served as Executive Vice President of Global Sales and Vice President of International Operations. Prior to joining RITA, he gained leadership experience at Computer Motion, Tyco Healthcare and U.S. Surgical. Mr. Soto graduated from the British Royal Navy with a degree in electronic engineering and has a diploma in medical marketing from the University of California at Los Angeles, Calif.
AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.
AngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, including Navilyst Medical and its products, R&D capabilities, infrastructure and employees as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2012. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.